Article Versions Notes

Jiang S, Huang J, He H, Liu Y, Liang L, Sun X, Li Y, Cong L, Qing B, Jiang Y. NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. Cancers. 2022; 14(18):4395. https://doi.org/10.3390/cancers14184395

Jiang, Shiyao, Jingjing Huang, Hua He, Yueying Liu, Lu Liang, Xiaoyan Sun, Yi Li, Li Cong, Bei Qing, and Yiqun Jiang. 2022. "NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma" Cancers 14, no. 18: 4395. https://doi.org/10.3390/cancers14184395

Jiang, S., Huang, J., He, H., Liu, Y., Liang, L., Sun, X., Li, Y., Cong, L., Qing, B., & Jiang, Y. (2022). NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. Cancers, 14(18), 4395. https://doi.org/10.3390/cancers14184395